<DOC>
	<DOCNO>NCT01928147</DOCNO>
	<brief_summary>PPI-383 antiviral agent ( inhibitor hepatitis C virus NS5B polymerase ) develop potential treatment hepatitis C virus infection . This study do assess dose-related safety tolerance PPI-383 give healthy volunteer 5 day ( Part I study ) hepatitis C patient 3 day ( Part II ) . In addition , study assess much PPI-383 absorb bloodstream . In Part II , dose-related effect PPI-383 amount hepatitis C virus patient ' bloodstream ( serum HCV RNA level ) also assess .</brief_summary>
	<brief_title>A Phase 1a/1b Study PPI-383 Healthy Adults Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Part I volunteer ( single multiple dose ) key inclusion criterion Healthy male Age 18 55 year Body mass index ( BMI ) 18 32 kg/m2 Part II patient key inclusion criterion Males , females nonchildbearing potential Age 18 65 year Chronic hepatitis C , absence know liver disease Seropositive HCV antibody ( HCV Ab ) HCV RNA least previously Seropositive HCV Ab screen Serum HCV RNA &gt; 5 log10 IU/mL screen HCV gt1 Treatmentna√Øve hepatitis C : BMI 18 35 kg/m2 Otherwise good health , without severe clinically significant chronic recurrent condition require frequent medical intervention continual pharmacologic management , except antihypertensive use No medical psychosocial condition would potentially interfere subject 's ability comply study assessment visit schedule . Part II patient key exclusion criterion Seropositive human immunodeficiency virus ( HIV ) antibody hepatitis B virus ( HBV ) surface antigen ( HBsAg ) Signs symptom decompensated liver disease Evidence cirrhosis hepatocellular carcinoma Diabetes Mellitus treat insulin hypoglycemic agent Asthma require hospital admission within precede 12 month History alcohol abuse illicit drug use could interfere patient 's compliance protocol requirement Any follow laboratory value screen Haemoglobin ( Hgb ) &lt; 11 g/dL woman 12 g/dL men White blood cell count &lt; 4,000/mm3 Absolute neutrophil count ( ANC ) &lt; 1800 per mm3 Platelet count &lt; 100,000 per mm3 Serum creatinine &gt; upper limit normal ( ULN ) central study laboratory Serum albumin &lt; 3.4 g/dL Total bilirubin &gt; 2.0 mg/dL Clinically significant abnormality electrocardiogram ( ECGs ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>NS5B polymerase inhibitor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Genotype 1</keyword>
</DOC>